Nektar Therapeutics NKTR announced that it has initiated the first two registrational studies in the phase III ZENITH AD ...

Apogee Therapeutics (APGE) on Monday announced positive 52-week maintenance data from part A of the phase 2 APEX clinical trial of zumilokibart (APG777), a potential best-in-class anti-IL-13 antibody, ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...

Interim clinical data from APG777 Phase 1 healthy volunteers study exceeded all trial objectives and achieved a half-life of approximately 75 days with a potentially best-in-class profile 16-week ...

Bambusa Therapeutics, Inc. (Bambusa Therapeutics or Bambusa), a clinical-stage biotechnology company developing next-generation, long-acting bispecific antibodies designed for immunology and ...

Sanofi has retreated from a plan to file its anti-OX40L antibody amlitelimab for approval as a treatment for atopic ...

Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews Paris, July 24, 2026. Sanofi today announced the discontinuation of clinical development of ...